Phenomenon of synergism of immunodepressive drugs (addition of kempas to the protocol of immunodepression)


Cite item

Full Text

Abstract

Aim. To determine kempas ability to potentiate the action of simulneously used daklizumab.
Material and methods. Kempas was given to 7 patients twice: 18-21 days before transplantation and on the day of transplantation after plasmapheresis. The control group consisted of 9 patients who received induction immunodepression only with daklizumab. By demographic and clinico-laboratory parameters the groups were identical. The assessment was made by duration of the interval between administration of daklizumab.
Results. Patients given kempas had longer intervals between daklizumab administration (the difference was significant).
Conclusion. Kempas potentiates an immunodepressive action of daklizumab

References

  1. Firch J. D., Miller J., Deierhoi M. H. et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression, after cadaveric renal transplantation. Transplantation 1997; 63: 977.
  2. The Tricontinental Mofetil Renal Transplantation Study Group. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaver transplantation. Transplantation 1996; 61: 1029.
  3. Ojo A. O., Meier-Krieshe H. U., Hanson J. A. et al. Mycophenolate mofetil reduces late renal allograft loss independent rejection. Transplantation 2000; 69: 2405.
  4. Burke J. R. Jr., Pirsh J. D., Ramon E. L. et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N. Engl. J. Med. 1994; 331: 358.
  5. Harharan S., Johnson C. P., Bresnahan R. A. et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. 2000; 342: 605.
  6. Nashan В., Light S., Hardie I. R. et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110.
  7. Ciancio G., Burke G. V., Suzart K. et al. Daclizumab induction, tacrolimus, mycophenalate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100.
  8. Tran H. T., Acharya M. K., McKay D. B. et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J. Am. Soc. Nephrol. 2000; 11: 1903.
  9. Kuypers D. R., Evenepoel P., Maes B., et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin. Transplant. 2003; 75: 37.
  10. Vincenti F., Ramos E., Brattstrom C. et al. Multicenter trial exploring calcineurine inhibitors-avoidance in renal reansplantation. Transplantation 2001; 71: 1282.
  11. Takada M., Chandraker A., Nadeau K. C. et al. The role of the B7 costimulatory pathway in experimental cold ischemia/ reperfusion injury. J. Clin. Invest. 1997; 100 (5): 1199-1203.
  12. Thai N. L., Abu-Elmagd K., Khan A. et al. Pancreatic transplantation at the University of Pittsburgh. Clin. Transplant. 2004, 21: 205-214.
  13. Shapiro R., Ellis D., Tan H. P. et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J. Pediatr. 2006; 148 (6): 813-818.
  14. Larsen C. P., Ritchie S. C., Hendrix R. et al. Regulation of immunostimulatory function and costimulatorymolecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol. 1994; 152: 5208-5219.
  15. Watson C. J., Bradely J. A., Friend P. J. et al. Alemtuzumab (CAMPATH 1Н) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am. J. Transplant. 2005; 5 (6): 1347-1538.
  16. Chanraker A., Takada M., Nadeau K. C. et al. CD28-B7 blockade in organ dysfunction secondary to cold ishemia/reperfusion injury. Kidney Int. 1997; 52: 1678-1684.
  17. Goes N., Urmos J., Ramassar V., Halloran P. F. Ishemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon-gamma, transforming growth factor-beta l:granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation 1995; 59: 565-572.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies